Heterologous booster ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 13 | Multiple sclerosis/Neuromyelitis optica | 1 |
13. Multiple sclerosis/Neuromyelitis optica
Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05081271 (ClinicalTrials.gov) | October 15, 2021 | 14/10/2021 | COVID-19 Booster Vaccination in Persons With Multiple Sclerosis | COVID-19 Booster Vaccination in Persons With Multiple Sclerosis | Multiple Sclerosis | Biological: Homologous booster;Biological: Heterologous booster | Griffin Hospital | Yale-Griffin Prevention Research Center;Multiple Sclerosis Treatment Center | Terminated | 18 Years | N/A | All | 10 | Early Phase 1 | United States |